<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">c9orf72</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>C9ORF72</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>c9orf72</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=C9ORF72" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als/ftd" style="color:#ef9a9a">ALS/FTD</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">872 edges</a></td>
</tr>
</table>
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">c9orf72</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>C9ORF72</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>c9orf72</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=C9ORF72" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als/ftd" style="color:#ef9a9a">ALS/FTD</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">872 edges</a></td>
</tr>
</table>
The C9orf72 protein (Chromosome 9 Open Reading Frame 72) is encoded by the C9orf72 gene located on chromosome 9p21.1, representing the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The discovery of the hexanucleotide repeat expansion (GGGGCC) in this gene in 2011 transformed our understanding of the ALS-FTD spectrum and revealed C9orf72 as a central nexus linking genetic susceptibility, molecular pathogenesis, and therapeutic targeting in neurodegeneration[@renton2011]. The C9orf72 protein belongs to the DENN (Differentially Expressed in Normal and Neoplastic cells) domain family, functioning as a guanine nucleotide exchange factor (GEF) for Rab GTPases involved in endolysosomal trafficking and autophagy[@gao2015].
The hexanucleotide repeat expansion in C9orf72 accounts for approximately 40% of familial ALS cases, 25% of familial FTD cases, and a significant proportion of ALS-FTD overlap cases[@beckers2019]. The pathogenesis involves multiple mechanisms including loss of C9orf72 protein function (haploinsufficiency), toxic RNA gain-of-function from repeat-containing transcripts, and dipeptide repeat proteins (DPRs) translated from the expansion. This complex disease mechanism has made C9orf72 one of the most intensively studied targets in neurodegeneration research.
The C9orf72 protein is a 481-amino acid protein with an approximate molecular weight of 54 kDa. It contains several functional domains critical to its cellular functions:
N-terminal DENN Domain (residues 1-300): The core catalytic domain responsible for Rab GTPase GEF activity. The DENN domain is evolutionarily conserved and shared with other Rab GEFs, though C9orf72 exhibits specific substrate preferences and cellular functions unique to neuronal and myeloid cell types. This domain promotes GDP release from Rab proteins, facilitating their transition to the active GTP-bound state.
Central Linker Region (residues 300-400): A flexible region mediating protein-protein interactions and complex formation with SMCR8 and WDR41. This region contains multiple phosphorylation sites that regulate complex formation and GEF activity.
C-terminal Winged-Helix Domain (residues 400-481): Involved in substrate recognition and localization to endosomal membranes. This domain helps target the C9orf72-SMCR8-WDR41 complex to specific cellular compartments.
The protein localizes to the cytoplasm, where it associates with endosomes, lysosomes, and autophagosomes. Subcellular fractionation studies demonstrate enrichment in membrane fractions, consistent with its role in trafficking events.
C9orf72 undergoes several post-translational modifications that regulate its cellular function:
Phosphorylation: Multiple serine/threonine sites are phosphorylated in vivo, potentially regulating complex formation with SMCR8 and WDR41, as well as GEF activity toward Rab GTPases.
Ubiquitination: C9orf72 can be ubiquitinated, targeting it for proteasomal degradation or altering its interaction network. The ubiquitination status affects protein stability and function.
Sumoylation: Sumoylation has been reported and may influence subcellular localization and protein-protein interactions.
As a DENN domain protein, C9orf72 functions as a guanine nucleotide exchange factor (GEF) for specific Rab GTPases, predominantly Rab proteins involved in the autophagy-lysosome pathway. The C9orf72-SMCR8-WDR41 complex exhibits activity toward Rab proteins including:
Rab5: Regulates early endosome fusion and trafficking, controlling the initial stages of endocytic pathway progression.
Rab8: Controls exocytosis and Golgi function, affecting secretory vesicle trafficking and plasma membrane composition.
Rab11: Mediates recycling endosome dynamics, important for receptor recycling and membrane retrieval.
Rab39: A brain-enriched Rab implicated in neuronal function, with specific roles in synaptic vesicle trafficking.
This GEF activity is essential for coordinating membrane trafficking events critical to neuronal homeostasis. The C9orf72-SMCR8-WDR41 complex forms a stable ternary complex that modulates GEF activity and cellular localization.
C9orf72 plays a central role in regulating autophagy, the cellular degradation pathway essential for protein quality control and organelle turnover:
Autophagy Initiation: C9orf72 localizes to the surface of nascent autophagosomes, facilitating the recruitment of autophagy machinery components. Loss of C9orf72 impairs autophagosome formation and leads to accumulation of damaged organelles and protein aggregates.
Lysosomal Function: Through its role in endolysosomal trafficking, C9orf72 supports lysosomal function and autophagosome-lysosome fusion. This is critical for the final degradation step in autophagy.
Cargo Selectivity: C9orf72 may contribute to selective autophagy by facilitating the recruitment of specific cargo receptors to forming autophagosomes.
The Rab GEF activity of C9orf72 directly links it to endolysosomal trafficking pathways. C9orf72 regulates:
Endosome Maturation: Through regulation of Rab5 and Rab7 activity, C9orf72 controls the progression of early endosomes to late endosomes and their fusion with lysosomes.
Cargo Sorting: C9orf72 influences the sorting of cargo within the endosomal system, determining whether materials are recycled to the plasma membrane or delivered to lysosomes for degradation.
Membrane Trafficking: The protein supports the bidirectional movement of vesicles between the Golgi, plasma membrane, and endosomal compartments.
C9orf72 is highly expressed in hematopoietic cells, with specific roles in:
Monocyte/Macrophage Function: C9orf72 regulates lysosomal trafficking in macrophages, affecting immune response and phagocytosis.
Hematopoiesis: C9orf72 haploinsufficiency affects hematopoietic stem cell function and may contribute to immune dysregulation in C9orf72-ALS/FTD patients.
These immune-related functions may contribute to the neuroinflammation observed in C9orf72-related disease[@schmitz2022].
The hexanucleotide repeat expansion in C9orf72 leads to disease through multiple mechanisms:
Loss of Function: Reduced C9orf72 protein expression due to reduced transcription from the expanded allele (haploinsufficiency). This compromises autophagy and endolysosomal function, leading to accumulation of damaged proteins and organelles.
RNA Toxicity: The expanded RNA transcripts form nuclear RNA foci that sequester essential RNA-binding proteins, disrupting RNA metabolism and splicing.
Dipeptide Repeat Proteins: Translation of the hexanucleotide repeat in all three reading frames produces dipeptide repeat proteins (DPRs) including poly-GA, poly-GP, poly-GR, poly-PA, and poly-PR. These DPRs are aggregation-prone and disrupt multiple cellular processes.
The relative contribution of each mechanism to disease pathogenesis remains an active area of investigation. Evidence suggests that both loss-of-function and gain-of-toxic mechanisms contribute to the observed phenotype.
One of the key pathogenic mechanisms involves disruption of nucleocytoplasmic transport:
The C9orf72 repeat expansion and associated DPRs disrupt nuclear pore complex function and impair the transport of molecules between the nucleus and cytoplasm. This affects:
mRNA Export: Impaired export of messenger RNAs from the nucleus to cytoplasm.
Protein Import: Reduced nuclear import of transcription factors and other nuclear-targeted proteins.
Nuclear Integrity: General disruption of nucleocytoplasmic compartmentation.
This defect may explain the widespread RNA metabolism and transcriptional dysregulation observed in C9orf72-ALS/FTD[@freibaum2015].
The loss of C9orf72 function compromises autophagy, leading to:
Protein Aggregate Accumulation: Impaired clearance of misfolded proteins, including TDP-43, which forms the characteristic inclusions in ALS/FTD.
Mitochondrial Dysfunction: Reduced mitophagy leads to accumulation of damaged mitochondria and subsequent cellular stress.
Organelle Dysfunction: General disruption of cellular quality control pathways.
Therapeutic approaches aimed at enhancing autophagy have shown promise in preclinical models of C9orf72-ALS[@sellier2016].
C9orf72 plays a role in microglial function and neuroinflammation:
Microglial Activation: Loss of C9orf72 in microglia leads to altered inflammatory responses and may contribute to disease progression.
Immune Dysregulation: Hematopoietic changes and altered monocyte function may affect central nervous system immune surveillance.
Targeting neuroinflammation represents a potential therapeutic strategy for C9orf72-related disease[@sudria2022].
The C9orf72 hexanucleotide repeat expansion (GGGGCC) is the most common genetic cause of ALS and FTD:
Normal Range: 2-8 repeats in healthy individuals.
Pathogenic Range: Hundreds to thousands of repeats in disease. Intermediate repeats (20-30) may show reduced penetrance.
Anticipation: Larger repeat expansions are generally associated with earlier disease onset in subsequent generations.
The mechanism of expansion involves replication slippage and possibly DNA repair pathway dysfunction.
C9orf72 repeat expansions exhibit:
Autosomal Dominant Inheritance: One expanded allele is sufficient to cause disease.
Variable Penetrance: Not all individuals with the expansion develop disease, suggesting modifier genes and environmental factors.
Anticipatory Pattern: Earlier onset in successive generations, particularly through paternal transmission.
The C9orf72 expansion causes a spectrum of clinical phenotypes:
Amyotrophic Lateral Sclerosis (ALS): Progressive motor neuron disease with muscle weakness, atrophy, and eventual respiratory failure.
Frontotemporal Dementia (FTD): Progressive decline in behavior, language, and executive function.
ALS-FTD Overlap: Patients with features of both conditions.
Parkinsonism: Some carriers develop parkinsonian features.
The phenotypic variability likely reflects genetic modifiers, repeat size, and environmental factors.
Antisense oligonucleotides (ASOs) and RNA interference approaches target the C9orf72 transcript:
ASO Therapy: ASOs can be delivered to the CNS via intrathecal injection and have shown efficacy in reducing C9orf72 expression and DPR production in preclinical models.
Allele-Selective Targeting: Some approaches aim to selectively silence the expanded allele while preserving expression from the normal allele.
Viral-Mediated Delivery: AAV-based approaches for sustained gene silencing are in development.
Clinical trials of ASOs targeting C9orf72 are ongoing.
Approaches to mitigate dipeptide repeat protein toxicity include:
Translation Inhibition: Targeting the unconventional translation of DPRs from the repeat RNA.
Aggregate Disruption: Small molecules that can dissolve DPR aggregates or prevent their formation.
Cellular Clearance: Enhancing cellular degradation pathways to clear existing DPRs.
Therapeutic strategies to restore C9orf72 function include:
Protein Replacement: Delivery of functional C9orf72 protein to compensate for loss of function.
Small Molecule Activators: Drugs that enhance the activity of remaining C9orf72 protein.
Trafficking Modulators: Compounds that improve endolysosomal function.
Additional therapeutic strategies include:
Neuroprotection: Antioxidants, anti-excitotoxic agents, and neuroprotective compounds.
Anti-inflammatory: Targeting neuroinflammation to slow disease progression.
Symptomatic: Addressing specific symptoms such as muscle cramps, spasticity, and behavioral changes.
Molecular testing for the C9orf72 repeat expansion is available:
PCR-Based Methods: Can detect expansions but may miss very large repeats.
Southern Blot: Gold standard for determining exact repeat size.
Repeat-Primed PCR: Sensitive for detecting expansions into the pathogenic range.
Genetic counseling is essential for patients and families considering testing.
Potential biomarkers under investigation include:
CSF DPR Levels: Poly-GA levels in cerebrospinal fluid correlate with disease progression.
Neurofilament Light Chain (NfL): Elevated in plasma and CSF, reflecting neuronal damage.
Autophagy Markers: Changes in autophagy-related proteins in patient samples.
Neuroimaging findings in C9orf72-ALS/FTD include:
Frontotemporal Atrophy: Characteristic patterns of frontotemporal brain volume loss.
Motor Cortex Involvement: Progressive loss of motor cortex integrity in ALS.
White Matter Changes: Diffuse white matter abnormalities in advanced disease.
Multiple animal models have been developed:
Fly Models: Drosophila models recapitulate DPR toxicity and behavioral phenotypes.
Mouse Models: Transgenic mice expressing C9orf72 repeats show motor deficits, cognitive changes, and neuropathology.
iPSC Models: Patient-derived induced pluripotent stem cells enable study of human neurons and glia.
These models have been essential for understanding disease mechanisms and testing therapeutic approaches.
Key challenges remaining include:
Mechanism Elucidation: Fully understanding how each pathogenic mechanism contributes to disease.
Biomarker Development: Identifying robust biomarkers for patient stratification and treatment monitoring.
Therapeutic Translation: Moving promising preclinical findings into clinical trials.
Active research areas include:
Single-Cell Approaches: Understanding cell-type-specific vulnerability in C9orf72-ALS/FTD.
Proteostasis: Targeting protein homeostasis pathways to enhance clearance of toxic proteins.
Epigenetics: Exploring how C9orf72 expansion affects epigenetic regulation.
Combination Therapies: Developing multi-target approaches to address the complex disease mechanism.
C9orf72 represents a paradigm for understanding the genetic and molecular basis of neurodegenerative disease. The identification of the hexanucleotide repeat expansion as the most common cause of ALS and FTD has transformed our understanding of these conditions and opened new avenues for therapeutic development. The protein's role as a Rab GEF linking endolysosomal trafficking to autophagy provides a mechanistic basis for understanding how its loss contributes to disease.
Despite significant progress, major challenges remain. The relative contributions of loss-of-function and gain-of-toxic mechanisms to disease pathogenesis remain incompletely understood. Effective therapies will likely need to address multiple aspects of the disease mechanism, potentially combining gene silencing with approaches to enhance protein clearance and protect neurons. The ongoing development of biomarkers for patient selection and treatment monitoring will be critical for successful clinical development.
Future research will continue to elucidate C9orf72 biology and identify novel therapeutic targets. The integration of genetic, molecular, and clinical approaches promises to accelerate progress toward effective treatments for this common and devastating form of neurodegenerative disease.
AlphaFold DB provides a full-length predicted structure for C9ORF72 (UniProt [Q96LT7](https://www.uniprot.org/uniprotkb/Q96LT7/entry), model v6) with mean pLDDT 83.44. View the model at [AlphaFold DB](https://alphafold.ebi.ac.uk/entry/Q96LT7) or download the [PDB file](https://alphafold.ebi.ac.uk/files/AF-Q96LT7-F1-model_v6.pdb).
Domain and region confidence from per-residue pLDDT:
UniProt function annotation: Acts as a guanine-nucleotide releasing factor (GEF) for Rab GTPases by promoting the conversion of inactive RAB-GDP to the active form RAB-GTP (PubMed:27103069, PubMed:27193190, PubMed:27617292, PubMed:28195531, PubMed:37821429). Acts as a GEF for RAB39A which enables HOPS-mediated autophagosome-lysosome membrane tethering and fusion in mammalian autophagy.
Subcellular localization: Cytoplasm, Nucleus, Cytoplasm, P-body, Cytoplasm, Stress granule, Endosome, Lysosome, Cytoplasmic vesicle, autophagosome, Autolysosome, Secreted, Cell projection, axon, Cell projection, growth cone, Perikaryon.
Curated disease associations include: Frontotemporal dementia and/or amyotrophic lateral sclerosis 1.
The following diagram shows the key molecular relationships involving C9orf72 Protein discovered through SciDEX knowledge graph analysis: